OncoMatch/Clinical Trials/NCT07295951
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Is NCT07295951 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including 14C-bleximenib and bleximenib for acute lymphoblastic leukemia.
Treatment: 14C-bleximenib · bleximenib — The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Biomarker criteria
Required: KMT2A (MLL) gene alteration
Required: NPM1 gene alteration
Required: NUP214 gene alteration
Required: NUP98 gene alteration
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify